目的 通过构建不良反应管理团队,临床药师直接参与口服靶向药物不良反应的管理,优化管理患者长期口服靶向药物安全性。方法 建立不良反应事件管理团队,临床药师对患者实施全程监护。收集我院54例口服吉非替尼的出院肺癌患者,对其在院期间实施用药教育,出院后定期电话随访,同时加强用药教育,指导不良反应的处理措施。调查药学监护后患者对靶向药物的认知度情况。结果 通过构建医、药、护医疗团队对口服靶向药物患者集中管理,临床药师直接参与患者长期口服靶向药物药学监护,定期随访为患者提供药学服务,可降低靶向药物的不良反应严重程度,提高患者对靶向药物的认识度及不良反应的接受度。结论 建立药师定期随访加强用药教育可预先管理长期口服靶向药物的不良反应,同时实现患者的自我管理,优化患者长期口服靶向药物的治疗结果,提高患者用药依从性和生活质量。
Abstract
OBJECTIVE To explore the role of clinical pharmacists in safety management of long-term administration of oral targeted drugs by establishing a team for management of adverse reactions and providing pharmaceutical care. METHODS Inpatients receiving oral gefitinib (250 mg QD) were enrolled in the study between January 2014 and December 2014. Clinical pharmacists provided education and instruction to patients on how to deal with adverse effects during gefitinib treatment. After the discharge, the clinical pharmacists supplied regular follow-up for patients. Finally, a survey of patients′ awareness of targeted drugs was conducted after the pharmaceutical care. RESULTS The pharmaceutical care could attenuate the severity of adverse reactions. It also improved patient acceptance and understanding of targeted drugs and reduced the adverse reactions. CONCLUSION Provision of regular follow-up and strengthened patient education by pharmacists can pre-manage the adverse drug reactions of long-term oral targeted drugs treatment, achieve patient self-management and improve their medication compliance and quality of life.
关键词
临床药师 /
靶向药物 /
不良反应 /
药学监护
{{custom_keyword}} /
Key words
clinical pharmacist /
targeted drug /
adverse reaction /
pharmaceutical care
{{custom_keyword}} /
中图分类号：
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LIU D Q, ZHAN S J. Research progress of molecular targeted therapy drugs[J]. Chin J Gen Surg (中国普外科杂志),2008,17(11):942-944.
[2] CTCE(2009)version 4. Common terminology criteria for adverse events v4.0 [S]. 2009:1-197.
[3] LIU M, ZHOU C H. Literature analysis of adverse drug reactions induced by gefitinib and erlotinib[J].Chin J Pharmacoepidemiol(药物流行病学杂志),2011,20(2):103-105.
[4] CHANG T, MEI D,ZHANG L, et al. New anticancer drugs-gefitinib[J].Chin Pharm J(中国药学杂志), 2006,41(12):958-979.
[5] PASSARO A, DI MAIO M, DEL SIQNORE E, et al. Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis[J].Clin Lung Cancer, 2014,15(4):207-212.
[6] HIRSH V, BLAIS N, BURKES R, et al. Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors[J].Curr Oncol, 2014,21(6):329-336.
[7] HU W W,YANG X X,XU B,et al. Efficacy of montmorillonite powder in combination with bifidobacterium lactobacillus triple viable capsule treat sorafenib-associated diarrhea [J].China Med Eng(中国医学工程), 2013,21(12):110-111.
[8] HUANG R Z, LIU X Y. The use of microecological preparations in digestive dseases system[J]. Eva Anal Drug Use Hosp China(中国医院用药评价与分析), 2006,6(3):156-158.
[9] LI L. Saccharomyces boulardiianti diarrhea[D].Jinan:Shangdong Polytechnic University, 2013.
[10] CHEN Z, MEI D,TANG Z Q. Prevention and treatments for adverse drug reactions of oral small molecular targeting drugs[J]. Chin J New Drugs(中国新药杂志), 2009,18(18):1807-1816.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(850 KB)
